Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

News Room

News Room Search
News Room List
NO Title Date Viewers
34 HanAll Biopharma Recorded Its Record-High Earnings Last Year 2020-02-27 322
33 HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3 (VELOS-2) Study at a Press Conference 2020-01-28 3875
32 HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease 2019-03-12 4372
31 HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S. 2018-10-29 3748
30 HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China 2018-10-01 4059
29 HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion 2018-08-14 3332
28 HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant 2018-07-11 4971
27 HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization (WHO) 2018-06-25 3843
26 HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036 (a new drug for dry eye syndrome) in the U.S. 2018-05-29 3754
25 IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American Society of Clinical Oncology 2018-05-24 3169
1 2 3 현재 페이지4 5 6 7